Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi ...
Ripple executive Luke Judges shares insights on XRP’s growth, developer focus and lessons drawn from Solana’s network ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback